LY3325656 is a GPR142 agonist suitable for clinical testing in human. LY3325656 demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. LY3325656 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
Molecular Weight:
448.44
CAS Number:
[1998714-25-2]
Formula:
C21H23F3N6O2
Target:
Others
T70005
* VAT and and shipping costs not included. Errors and price changes excepted